 | | Anno I – Numero 1 | Comitato scientifico editoriale: Saverio Cinieri, Umberto Malapelle
Editore: Intermedia, Direttore Responsabile: Mauro Boldrini | | |
The Diversity of Liquid Biopsies and Their Potential in Breast Cancer Management
Analyzing blood as a so-called liquid biopsy in breast cancer (BC) patients has the potential to adapt therapy management. Circulating tumor cells (CTCs), extracellular vesicles (EVs), cell-free DNA (cfDNA) and other blood components mirror the tumoral heterogeneity and could support a range of clinical decisions. Multi-cancer early detection tests utilizing blood are advancing but are not part of any clinical routine yet. Liquid biopsy … Continua a leggere
|
ESR1 Gene Mutations and Liquid Biopsy in ER-Positive Breast Cancers: A Small Step Forward, a Giant Leap for Personalization of Endocrine Therapy?
The predominant forms of breast cancer (BC) are hormone receptor-positive (HR+) tumors characterized by the expression of estrogen receptors (ERs) and/or progesterone receptors (PRs). Patients with HR+ tumors can benefit from endocrine therapy (ET). Three types of ET are approved for the treatment of HR+ BCs and include selective ER modulators, aromatase inhibitors, and selective ER downregulators … Continua a leggere
ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer
Human epidermal growth factor receptor 2 (HER2)-low breast cancer has recently emerged as a targetable subset of breast tumors, based on the evidence from clinical trials of novel anti-HER2 antibody-drug conjugates. This evolution has raised several biological and clinical questions, warranting the establishment of consensus to optimally treat patients with HER2-low breast tumors. Between 2022 and 2023, the European Society … Continua a leggere
ESR1 mutations in HR+/HER2-metastatic breast cancer: Enhancing the accuracy of ctDNA testing
Activating mutations of the estrogen receptor alpha gene (ESR1) are common mechanisms of endocrine therapy (ET) resistance in hormone receptor-positive (HR + )/Human Epidermal Growth Factor Receptor 2 (HER2)-negative metastatic breast cancer (MBC). Recent clinical findings emphasize that both old and new generations of selective ER degraders (SERDs) demonstrate enhanced clinical effectiveness in patients with MBC who have … Continua a leggere
Testing for ESR1 Mutations to Guide Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update
ASCO Rapid Recommendations Updates highlight revisions to select ASCO guideline recommendations as a response to the emergence of new and practice-changing data. The rapid updates are supported by an evidence review and follow the guideline development processes outlined in the ASCO Guideline Methodology Manual. The goal of these articles is to disseminate updated recommendations, in a timely manner, to better inform … Continua a leggere
|
Making Palliative Care a part of your Oncology Practice
I mercoledì dell’oncologia
Webinar , 10 gennaio 2024 dalle 17.00 alle 18.15
Corso per Quality Assurance e Auditor
FAD , 11 gennaio – 18 marzo 2024
Back from San Antonio 2024
Genova, 12 – 13 gennaio 2024
Quali le sfide da affrontare nel Tumore Germinale del testicolo
I mercoledì dell’oncologia
Webinar , 17 gennaio 2024 dalle 17.00 alle 18.15
Best from San Antonio 2023
Webinar ECM, 25 gennaio 2024
La Ricerca alla Portata del Paziente 3.0
Roma, 26 gennaio 2024
SCUOLA DI METODOLOGIA DELLA RICERCA CLINICA 2024
Negrar (VR), 26 – 27 gennaio 2024
| Questi e altri appuntamenti si possono consultare sul sito AIOM: www.aiom.it
|
| |
© 2023 Editore: Intermedia srl Via Lunga 16a Brescia, BS 25124 Italy
tel. 030 226105 – 388 8896214 – Reg. Trib. di Brescia n. 35/2001 del 2/7/2001
Iscrizione al Registro degli Operatori di Comunicazione N. 4867
Per contattare la redazione e commentare le notizie clicca qui
Ricevi questa email perché sei iscritto alla newsletter AIOM Cancellati
Privacy
“Realizzata con il supporto non condizionante di Menarini Stemline ”
|
|
|
|
|